ClinicalTrials.gg

Program

EV71

A development code. Also written as “EV71 vaccine”, “EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)” and “EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)”.

Its studies are mostly in Hand, Foot and Mouth Disease · Enterovirus Infections · Infections, led by 3 companies.

Furthest: phase 4, since Sep 4, 201718 company-led studies, 1 open or runningNext primary completion: Jan 9, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech141 open or runningphase 4since Sep 4, 2017Jan 7, 2011Jan 9, 2027NCT07793175
Enimmune30 open or runningphase 3since Oct 18, 2021May 16, 2016none ahead
Sinopharm10 open or runningphase 4since Sep 15, 2019Sep 15, 2019none ahead

Also a collaborator on its studies: changchun-institute-of-biological-products-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jan 7, 2011.

  1. Jan 2, 2012Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT01507857 · 10,077 enrolled · China
  2. Jul 5, 2012Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT01636245 · 1,400 enrolled · China
  3. Mar 13, 2013Phase 2 study in InfectionsSinovac Biotech · NCT01812135 · China
  4. May 16, 2016Enimmune's first study: phase 2 study in Enterovirus InfectionsNew to EnimmuneEnimmune · NCT02777411 · 122 enrolled · Taiwan
  5. Aug 4, 2016Phase 2 study in Enterovirus InfectionsEnimmune · NCT03268083 · 140 enrolled · Taiwan
  6. Sep 4, 20172 phase 4 studies in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03274102, NCT03278132
  7. Mar 2, 2019Phase 4 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03873740 · 300 enrolled · China
  8. Mar 29, 2019Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03909074 · 900 enrolled · China
  9. Sep 15, 2019Sinopharm's first study: phase 4 study in Enterovirus InfectionsNew to SinopharmSinopharm · NCT04091880 · 1,134 enrolled · China
  10. Oct 18, 2021Phase 3 study in Enterovirus InfectionsEnimmune · NCT05099029 · 3,982 enrolled · Taiwan, Vietnam
  11. Sep 15, 2023Phase 2 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT06063057 · 744 enrolled · China
  12. Dec 22, 2024Phase 2 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT06754384 · 552 enrolled · China
  13. Jun 10, 2025Phase 4 study in EV71 VaccineSinovac Biotech · NCT07026500 · 720 enrolled · China
  14. Aug 25, 2026No phase study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT07793175 · 320 planned · Vietnam

Ahead

  1. Jan 9, 2027Primary completion: no phase study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT07793175

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07793175Hand, Foot and Mouth Disease · Vietnam–Not yet recruitingSinovac BiotechJan 9, 2027320
NCT07026500EV71 Vaccine · China4CompletedSinovac BiotechApr 30, 2020720
NCT06754384Hand, Foot and Mouth Disease · China2CompletedSinovac BiotechDec 30, 2025552
NCT06063057Hand, Foot and Mouth Disease · China2CompletedSinovac BiotechDec 19, 2025744
NCT05099029Enterovirus Infections · Taiwan, Vietnam3CompletedEnimmuneJul 31, 20243,982
NCT04091880Enterovirus Infections · China4CompletedSinopharmJan 6, 20201,134
NCT03909074Hand, Foot and Mouth Disease · China3CompletedSinovac BiotechJun 17, 2019900
NCT03873740Hand, Foot and Mouth Disease · China4CompletedSinovac BiotechJan 21, 2019300
NCT03278132Hand, Foot and Mouth Disease · China4CompletedSinovac BiotechSep 15, 2017120
NCT03274102Hand, Foot and Mouth Disease · China4CompletedSinovac BiotechNov 1, 2017780
NCT03268083Enterovirus Infections · Taiwan2CompletedEnimmuneAug 2017140
NCT02777411Enterovirus Infections · Taiwan2CompletedEnimmuneJan 2016122
NCT01812135Infections · China2WithdrawnSinovac BiotechNov 20110
NCT01636245Hand, Foot and Mouth Disease · China3CompletedSinovac BiotechSep 20121,400
NCT01507857Hand, Foot and Mouth Disease · China3CompletedSinovac BiotechMar 201310,077
NCT01421121Infections · China2CompletedSinovac BiotechSep 2011540
NCT01273246Hand, Foot and Mouth Disease · China1CompletedSinovac BiotechJun 2011132
NCT01273233Infections · China1CompletedSinovac BiotechFeb 201136

How it is read

Names in the registry

  • “EV71 vaccine”, 3 entries
  • “EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)”, 2 entries
  • “EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)”, 2 entries
  • “Enterovirus type EV71 vaccine (Vero cell), Inactivated”, 1 entry
  • “EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)”, 1 entry

Codes read as this program: ENTEROVIRUS71VACCINE, EV71.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.